CSII Stock - Cardiovascular Systems, Inc.
Unlock GoAI Insights for CSII
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $236.22M | $258.97M | $236.54M | $248.02M | $217.04M |
| Gross Profit | $172.78M | $197.84M | $187.79M | $200.34M | $177.56M |
| Gross Margin | 73.1% | 76.4% | 79.4% | 80.8% | 81.8% |
| Operating Income | $-35,806,000 | $-11,933,000 | $-26,772,000 | $-825,000 | $-1,700,000 |
| Net Income | $-36,933,000 | $-13,421,000 | $-27,236,000 | $-255,000 | $1.71M |
| Net Margin | -15.6% | -5.2% | -11.5% | -0.1% | 0.8% |
| EPS | $-0.94 | $-0.35 | $-0.79 | $-0.01 | $0.05 |
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 21st 2022 | Barclays | Initiation | Equal Weight | $15 |
| December 14th 2022 | Lake Street | Initiation | Buy | $25 |
Earnings History & Surprises
CSIIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Feb 7, 2024 | — | — | — | — |
Q4 2023 | Nov 1, 2023 | — | — | — | — |
Q3 2023 | Jul 31, 2023 | $-0.12 | — | — | — |
Q2 2023 | May 3, 2023 | $-0.15 | — | — | — |
Q1 2023 | Feb 8, 2023 | $-0.15 | $-0.20 | -33.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $-0.14 | $-0.23 | -64.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.10 | $-0.22 | -120.0% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.10 | $-0.15 | -50.0% | ✗ MISS |
Q1 2021 | Feb 3, 2021 | $-0.07 | $-0.00 | +97.9% | ✓ BEAT |
Q4 2020 | Nov 4, 2020 | $-0.23 | $-0.05 | +78.3% | ✓ BEAT |
Q3 2020 | Aug 4, 2020 | $-0.44 | $-0.43 | +2.3% | ✓ BEAT |
Q2 2020 | May 5, 2020 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q1 2020 | Feb 5, 2020 | $-0.01 | $-0.10 | -627.3% | ✗ MISS |
Q4 2019 | Oct 29, 2019 | $-0.09 | $-0.17 | -88.9% | ✗ MISS |
Q3 2019 | Aug 6, 2019 | $0.04 | $0.04 | +7.7% | ✓ BEAT |
Q2 2019 | May 1, 2019 | $0.01 | $0.02 | +160.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about CSII
What is CSII's current stock price?
What is the analyst price target for CSII?
What sector is Cardiovascular Systems, Inc. in?
What is CSII's market cap?
Does CSII pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CSII for comparison